HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

AuthorsGrant D Stewart, Bradley C Leibovich, Sylvie Negrier, Robert A Figlin
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 35 Issue 35 Pg. 3895-3897 (12 10 2017) ISSN: 1527-7755 [Electronic] United States
PMID29068785 (Publication Type: Editorial, Comment)
Chemical References
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib
Topics
  • Carcinoma, Renal Cell (surgery)
  • Humans
  • Indazoles
  • Kidney Neoplasms (surgery)
  • Neoplasm Recurrence, Local
  • Nephrectomy
  • Pyrimidines
  • Sulfonamides

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: